In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on ATAI Life Sciences (ATAI – Research Report), with ...

As the U.S. stock market navigates a week of fluctuating earnings reports and economic indicators, investors are keenly observing opportunities across various sectors. Penny stocks, often associated ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on ATAI Life Sciences (ATAI – Research Report). The company’s ...

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients.

Shares of companies developing psychedelic treatments jumped while those of vaccine makers slipped after a Senate committee advanced the nomination of Robert F. Kennedy Jr. to lead the Health and ...

Atai reported “dose-dependent and robust subjective effects” at these higher doses, with 13 out of 14 participants scoring greater than 7 out of 10 on the Subjective Intensity Rating Scale at ...

He has a wealth of experience that we believ NEW YORK and BERLIN, Oct. 15, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage ...

Beckley Psytech has announced that it has received substantial strategic investment from Germany-based atai Life Sciences, totalling $50 million, to accelerate the clinical development of short ...